Forest, Ironwood constipation drug hit with 3-month US delay
This article was originally published in Scrip
Executive Summary
Investors showed little worry on 23 April over a three-month delayed imposed by the US FDA on the new drug application for Forest's and Ironwood's experimental constipation drug linaclotide, with both firms' stock only slightly dinged.